On the mechanism of fibrin-specific plasminogen activation by staphylokinase. 1991

H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.

The mechanism of plasminogen activation by recombinant staphylokinase was studied both in the absence and in the presence of fibrin, in purified systems, and in human plasma. Staphylokinase, like streptokinase, forms a stoichiometric complex with plasminogen that activates plasminogen following Michaelis-Menten kinetics with Km = 7.0 microM and k2 = 1.5 s-1. In purified systems, alpha 2-antiplasmin inhibits the plasminogen-staphylokinase complex with k1(app) = 2.7 +/- 0.30 x 10(6) M-1 s-1 (mean +/- S.D., n = 12), but not the plasminogen-streptokinase complex. Addition of 6-aminohexanoic acid induces a concentration-dependent reduction of k1(app) to 2.0 +/- 0.17 x 10(4) M-1 s-1 (mean +/- S.D., n = 5) at concentrations greater than or equal to 30 mM, with a 50% reduction at a 6-aminohexanoic acid concentration of 60 microM. Staphylokinase does not bind to fibrin, and fibrin stimulates the initial rate of plasminogen activation by staphylokinase only 4-fold. Staphylokinase induces a dose-dependent lysis of a 0.12-ml 125I-fibrin-labeled human plasma clot submersed in 0.5 ml of citrated human plasma; 50% lysis in 2 h is obtained with 17 nM staphylokinase and is associated with only 5% plasma fibrinogen degradation. Corresponding values for streptokinase are 68 nM and more than 90% fibrinogen degradation. In the absence of a fibrin clot, 50% fibrinogen degradation in human plasma in 2 h requires 790 nM staphylokinase, but only 4.4 nM streptokinase. These results suggest the following mechanism for relatively fibrin-specific clot lysis with staphylokinase in a plasma milieu. In plasma in the absence of fibrin, the plasminogen-staphylokinase complex is rapidly neutralized by alpha 2-antiplasmin, thus preventing systemic plasminogen activation. In the presence of fibrin, the lysine-binding sites of the plasminogen-staphylokinase complex are occupied and inhibition by alpha 2-antiplasmin is retarded, thus allowing preferential plasminogen activation at the fibrin surface.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D010958 Plasminogen Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent. Profibrinolysin,Glu-Plasminogen,Glutamic Acid 1-Plasminogen,Glutamyl Plasminogen,1-Plasminogen, Glutamic Acid,Glu Plasminogen,Glutamic Acid 1 Plasminogen,Plasminogen, Glutamyl
D003488 Cyanogen Bromide Cyanogen bromide (CNBr). A compound used in molecular biology to digest some proteins and as a coupling reagent for phosphoroamidate or pyrophosphate internucleotide bonds in DNA duplexes. Bromide, Cyanogen
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin

Related Publications

H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
November 1996, American journal of hematology,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
October 1994, Thrombosis research,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
February 1960, Nature,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
August 1994, Blood,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
January 1975, Acta biochimica Polonica,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
January 1993, Methods in enzymology,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
August 1994, Biological & pharmaceutical bulletin,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
November 1996, The Journal of biological chemistry,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
July 2007, Biochemistry. Biokhimiia,
H R Lijnen, and B Van Hoef, and F De Cock, and K Okada, and S Ueshima, and O Matsuo, and D Collen
July 1989, Biochemical and biophysical research communications,
Copied contents to your clipboard!